Alia Therapeutics is working to engineer novel and disruptive CRISPR tools for gene editing. We focus on the discovery of novel microbiome-derived CRISPR nucleases and the development of innovative delivery methods for the treatment of incurable genetic diseases. Our unique discovery platform aims to identify and optimize nucleases derived from the human microbiome to target specific diseases. Our approach unleashes the full potential of the CRISPR technology and overcomes its main limitations: selectivity, efficacy, flexibility and delivery. Alia was founded in 2018 and received seed financing from Sofinnova Partners, BiovelocITA, the first Italian biotech startup accelerator, and other Italian investors.